Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395517 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL747726 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL746351 | 0.95 | CCR2 (0.90) | CCR2KCNH2 | |
| SCHEMBL744288 | 0.89 | CCR2 (0.89) | CCR2KCNH2 | |
| SCHEMBL744287 | 0.89 | CCR2 (0.89) | CCR2KCNH2 | |
| SCHEMBL745716 | 0.89 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL743857 | 0.89 | CCR2 (0.84) | CCR2KCNH2 | |
| SCHEMBL745717 | 0.89 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL765257 | 0.89 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL746250 | 0.89 | CCR2 (1.00) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | claimed |
| US-20250171546-A1 | DUPILUMAB FOR TREATMENT OF COVID-19 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-29 | — | — | US | disclosed |
| CN-111247163-B | Screening assays, modulators and modulators of progressive glycation end product Receptor (RAGE) activation | 莫纳施大学 | 2024-11-26 | — | — | CN | disclosed |
| US-11771759-B2 | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | FUDAN UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| WO-2023164655-A1 | DUPILUMAB FOR TREATMENT OF COVID-19 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20220175912-A1 | IMMUNOPOTENTIATOR, IMMUNOTHERAPEUTIC PHARMACEUTICAL COMPOSITION AND ITS PREPARATION AND USE | FUDAN UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |